Roche and Zealand Pharma entered a transformative $5.3 billion partnership deal to co-develop and co-commercialize petrelintide, an amylin analog for weight management13
Roche will pay $1.65 billion upfront with up to $5.3 billion total in milestone payments13
Phase 2 petrelintide data from the ZUPREME program was expected in the first quarter of 202624
Petrelintide showed potential for weight loss comparable to GLP-1 drugs with a better tolerability profile in clinical and pre-clinical studies1
Amylin analogs like petrelintide are considered the next generation of obesity medicines after current GLP-1 drugs like Novo Nordisk's Wegovy and Eli Lilly's Zepbound1
Zealand Pharma and Roche plan to advance petrelintide monotherapy into a comprehensive Phase 3 program in the second half of 20264
Zealand Pharma is positioned for its most catalyst-rich year in company history, with potential milestone payments from Roche totaling USD 700 million in 202624
The partnership also includes plans to initiate Phase 2 testing of a petrelintide/CT-388 combination (amylin plus GLP-1/GIP) in the first half of 20264
Sources:
1. https://www.nasdaq.com/articles/nvo-stock-slips-4-roche-inks-obesity-drug-deal-zealand
2. https://www.investing.com/news/earnings/zealand-pharma-reports-blockbuster-2025-on-roche-collaboration-4512640
3. https://www.biopharmadive.com/news/roche-zealand-license-obesity-drug-amylin-petrelinitide/742278/
4. https://www.globenewswire.com/news-release/2026/02/19/3240768/0/en/Zealand-Pharma-Announces-Financial-Results-for-the-Full-Year-2025.html